Patents Assigned to Duramed Pharmaceuticals, Inc.
-
Patent number: 8227454Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: June 23, 2011Date of Patent: July 24, 2012Assignee: Duramed Pharmaceuticals, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Patent number: 7989436Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: May 27, 2010Date of Patent: August 2, 2011Assignee: Duramed Pharmaceuticals, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Patent number: 7749989Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: November 24, 2008Date of Patent: July 6, 2010Assignee: Duramed Pharmaceuticals, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Publication number: 20100063019Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 ?g per day of norgestimate.Type: ApplicationFiled: September 8, 2009Publication date: March 11, 2010Applicants: Duramed Pharmaceuticals, Inc., Jencap Research Ltd.Inventors: Robert F. CASPER, Gary A. SHANGOLD, Militza K. AUSMANAS
-
Patent number: 7615545Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.Type: GrantFiled: August 17, 2007Date of Patent: November 10, 2009Assignee: Duramed Pharmaceuticals, Inc.Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold
-
Publication number: 20090261014Abstract: A dispenser including a first dispensing portion including one group of storage units for each of ten to twenty-eight days, and a second dispensing portion, including at least one storage unit for each of seventeen to thirty days. In the first dispensing portion, a first set includes a group of four storage units for each day, a second set includes a group of three storage units for each day, and a third set includes a group of two storage units for each day. The first dispensing portion contain a progestin. In the second dispensing portion, the first fourteen storage units contain a placebo and the remaining storage units contain a progestin. First and second dispensing portions may be provided as separate dispensing packs, or as a multi-pack of second dispensing portions. The dispenser is useful for treatment of acute episodes of dysfunctional uterine bleeding (DUB) and maintenance treatment for preventing future episodes of DUB.Type: ApplicationFiled: July 1, 2009Publication date: October 22, 2009Applicant: Duramed Pharmaceuticals, Inc.Inventors: Kathy Reape, George Jones, JR.
-
Publication number: 20090247493Abstract: The present invention relates to methods of stimulating estrogen production that can be used to treat peri-menopausal or estrogen deficiency conditions utilizing regimens involving administration of estrogen and progestin, followed by a hormone-free period.Type: ApplicationFiled: January 29, 2007Publication date: October 1, 2009Applicant: Duramed Pharmaceuticals, Inc.Inventors: Charles E. Diliberti, Kathleen Z. Reape
-
Publication number: 20090188832Abstract: A child resistant drug package. The package includes a blister layer having at least one blister and a plurality of backing layers covering the blister layer. The backing layers include tabs that require sequential removal in order to gain access to the contents of the blister.Type: ApplicationFiled: January 30, 2009Publication date: July 30, 2009Applicant: Duramed Pharmaceuticals, Inc.Inventor: Tang B. Pham
-
Patent number: 7556150Abstract: A dispenser including a first dispensing portion including one group of storage units for each of ten to twenty-eight days, and a second dispensing portion, including at least one storage unit for each of seventeen to thirty days. In the first dispensing portion, a first set includes a group of four storage units for each day, a second set includes a group of three storage units for each day, and a third set includes a group of two storage units for each day. The first dispensing portion contain a progestin. In the second dispensing portion, the first fourteen storage units contain a placebo and the remaining storage units contain a progestin. First and second dispensing portions may be provided as separate dispensing packs, or as a multi-pack of second dispensing portions. The dispenser is useful for treatment of acute episodes of dysfunctional uterine bleeding (DUB) and maintenance treatment for preventing future episodes of DUB.Type: GrantFiled: June 7, 2005Date of Patent: July 7, 2009Assignee: Duramed Pharmaceuticals, Inc.Inventors: Kathy Reape, George Jones
-
Publication number: 20090170823Abstract: The present invention is directed to dosage regimens for emergency contraception using nonsteroidal progestins and pharmaceutical compositions and packages thereof. Such regimens are useful for females in need of emergency contraception.Type: ApplicationFiled: December 19, 2008Publication date: July 2, 2009Applicant: Duramed Pharmaceuticals, Inc.Inventor: Charles E. DILIBERTI
-
Publication number: 20090163454Abstract: The present invention relates to methods of step-down hormone treatment in which an estrogen and progestin combination regimen is administered for one or more cycles prior to administration of a lower dose hormone regimen containing a lower daily dosage amount of estrogen and/or progestin.Type: ApplicationFiled: December 22, 2008Publication date: June 25, 2009Applicant: Duramed Pharmaceuticals, Inc.Inventors: Howard Hait, Kathleen Reape
-
Patent number: 7497331Abstract: A child resistant drug package. The package includes a blister layer having at least one blister and a plurality of backing layers covering the blister layer. The backing layers include tabs that require sequential removal in order to gain access to the contents of the blister.Type: GrantFiled: May 4, 2005Date of Patent: March 3, 2009Assignee: Duramed Pharmaceuticals, Inc.Inventor: Tang B. Pham
-
Patent number: 7459445Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: February 6, 2007Date of Patent: December 2, 2008Assignee: Duramed Pharmaceuticals, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Publication number: 20080182828Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 ?g per day of norgestimate.Type: ApplicationFiled: November 27, 2007Publication date: July 31, 2008Applicants: Duramed Pharmaceuticals, Inc., Jencap Research Ltd.Inventors: Robert F. CASPER, Gary A. SHANGOLD, Militza K. AUSMANAS
-
Publication number: 20080125402Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.Type: ApplicationFiled: August 17, 2007Publication date: May 29, 2008Applicant: Duramed Pharmaceuticals, Inc.Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
-
Publication number: 20080051377Abstract: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.Type: ApplicationFiled: August 17, 2007Publication date: February 28, 2008Applicant: Duramed Pharmaceuticals, Inc.Inventors: Salah Ahmed, Madhu Shaik, Sanjeev Gupta
-
Patent number: 7320969Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.Type: GrantFiled: December 4, 2002Date of Patent: January 22, 2008Assignee: Duramed Pharmaceuticals, Inc.Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold
-
Publication number: 20070111975Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.Type: ApplicationFiled: October 30, 2006Publication date: May 17, 2007Applicant: Duramed Pharmaceuticals, Inc.Inventors: Charles Diliberti, Kathleen Reape, Lance Bronnenkant
-
Publication number: 20060249421Abstract: A child resistant drug package. The package includes a blister layer having at least one blister and a plurality of backing layers covering the blister layer. The backing layers include tabs that require sequential removal in order to gain access to the contents of the blister.Type: ApplicationFiled: May 4, 2005Publication date: November 9, 2006Applicant: Duramed Pharmaceuticals, Inc.Inventor: Tang Pham
-
Patent number: RE39861Abstract: A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.Type: GrantFiled: July 19, 2004Date of Patent: September 25, 2007Assignee: Duramed Pharmaceuticals, Inc.Inventor: Gary D. Hodgen